Status:
COMPLETED
Levetiracetam XR in Very Heavy Drinkers
Lead Sponsor:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions:
Alcoholism
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary objectives of this study are to assess the efficacy of levetiracetam XR in increasing the percentage of subjects with no heavy drinking days and in reducing the weekly percentage of heavy ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- The subject must be at least 18 years of age.
- The subject must have a DSM-IV diagnosis of current alcohol dependence.
- The subject must be seeking treatment for alcohol dependence and desires a reduction or cessation of drinking.
- The subject must be able to verbalize understanding of the consent form, able to provide written informed consent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English and able to complete the questionnaires required by the protocol.
- If the subject is female and of child bearing potential, she must agree to use at least one of the following methods of birth control, or she must be surgically sterile or postmenopausal:
- oral contraceptives
- contraceptive sponge
- patch
- barrier (diaphragm or condom)
- intrauterine contraceptive system
- levonorgestrel implant
- medroxyprogesterone acetate contraceptive injection
- complete abstinence from sexual intercourse, and/or
- hormonal vaginal contraceptive ring.
- The subject must be able to take oral medication, willing to adhere to the medication regimen, and willing to return for regular visits.
- The subject must complete all psychological assessments required at screening and baseline.
- The subject must provide evidence of stable residence in the last 2 months prior to randomization, have reasonable transportation arrangements to the study site, and have no plans to move within the next 3 months or unresolved legal problems. Subjects must provide contact information of someone, such as a family member, spouse, or significant other, who may be able to contact the subject in case of a missed clinic appointment.
- The subject must have a breath alcohol concentration (BAC) equal to 0.000 when s/he signed the informed consent document.
Exclusion
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00970814
Start Date
October 1 2009
End Date
October 1 2010
Last Update
August 28 2014
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins School of Medicine
Baltimore, Maryland, United States, 21224
2
Boston University School of Medicine
Boston, Massachusetts, United States, 02118
3
Dartmouth Medical School
Lebanon, New Hampshire, United States, 03755
4
University Of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104